CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $284,868 | -19.1% | 6,276 | 0.0% | 0.07% | -18.7% |
| Q2 2023 | $352,335 | +26.1% | 6,276 | +1.6% | 0.09% | +18.2% |
| Q1 2023 | $279,340 | +9.1% | 6,176 | -2.0% | 0.08% | +2.7% |
| Q4 2022 | $256,136 | -32.1% | 6,301 | +9.1% | 0.08% | -41.4% |
| Q3 2022 | $377,000 | +7.4% | 5,776 | 0.0% | 0.13% | -9.9% |
| Q2 2022 | $351,000 | +12.5% | 5,776 | +16.2% | 0.14% | +29.1% |
| Q1 2022 | $312,000 | -17.7% | 4,969 | -0.6% | 0.11% | +44.7% |
| Q4 2021 | $379,000 | -39.5% | 4,999 | -10.6% | 0.08% | -63.6% |
| Q3 2021 | $626,000 | -30.8% | 5,592 | 0.0% | 0.21% | -29.2% |
| Q2 2021 | $905,000 | +35.7% | 5,592 | +2.1% | 0.30% | +21.4% |
| Q1 2021 | $667,000 | -20.4% | 5,475 | 0.0% | 0.24% | -25.9% |
| Q4 2020 | $838,000 | – | 5,475 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |